BiotechTube
VintaBio

VintaBio

Philadelphia, United States· Est.
vintabio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $74M

Overview

VintaBio is a private, services-focused biotech company that provides a streamlined viral vector manufacturing platform for the gene and cell therapy industry. The company's proprietary VintaProcess™ is designed to significantly reduce process time and raw material costs while increasing yield and purity of vectors, particularly adeno-associated viruses (AAVs). With over 120 years of combined team experience and a state-of-the-art facility, VintaBio aims to make gene therapies more accessible by solving critical manufacturing bottlenecks for biopharma partners.

Gene TherapyCell Therapy

Technology Platform

VintaProcess™: A proprietary, small-footprint single-stream viral vector manufacturing process designed to reduce process time by 60%, cut raw material costs by 30%, increase high-purity vector production 5x, and achieve 90% full capsids for AAV vectors.

Funding History

2
Total raised:$74M
Series A$64M
Seed$10M

Opportunities

The company is positioned to capitalize on the severe manufacturing bottleneck in the rapidly growing gene and cell therapy market.
Its promise of faster, cheaper, and higher-quality viral vector production directly addresses the key scalability challenges facing therapy developers, especially as treatments move toward larger patient populations.

Risk Factors

Key risks include intense competition from larger, established CDMOs, the need to consistently validate its proprietary process at scale for diverse client needs, and dependence on the overall health and clinical success of the gene therapy sector.
As a private company, scaling its capital-intensive operations also presents a funding risk.

Competitive Landscape

VintaBio competes in the viral vector CDMO space against large, diversified players like Catalent, Lonza, and Thermo Fisher Scientific, as well as other focused CDMOs like Oxford Biomedica, Genezen, and Vigene Biosciences. Its differentiation hinges on the claimed superior efficiency and output of its proprietary VintaProcess™ platform.

More companies in Cell & Gene Therapy →More companies in United States →